Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Financings

Appili Therapeutics arranges $750,000 private placement

By The Northwire Desk — AI Analysis Nov 05, 2025 · 15:11 APLI · 0.025 Appili Therapeutics Inc
APLI · Price

Executive Summary

  • Appili Therapeutics Inc. announced a proposed non-brokered private placement of up to 30 million units at $0.025 per unit, targeting gross proceeds of up to $750,000.
  • Each unit consists of one Class A common share and one-half of one common share purchase warrant, with warrants exercisable at $0.05 per share for 36 months, subject to shareholder approval.
  • Net proceeds are intended for working capital and the development of product candidates, with an anticipated closing in November 2025.

Key Details

  • Transaction Structure: Non-brokered private placement of up to 30 million units.
  • Price: $0.025 per unit.
  • Gross Proceeds: Up to approximately $750,000.
  • Unit Composition: Each unit comprises one Class A common share and one-half of one common share purchase warrant.
  • Warrant Terms (Investors):
    • Exercise Price: $0.05 per common share.
    • Duration: 36 months from closing.
    • Condition: Exercisable only upon receipt of shareholder approval (excluding votes of warrant holders); approval to be sought no later than the next annual general meeting. If approval is not received, warrants are not exercisable.
  • Use of Proceeds: Primarily for working capital and financing the development of certain product candidates.
  • Closing Conditions: Subject to regulatory approvals, including Toronto Stock Exchange (TSX) approval.
  • Anticipated Closing: November 2025.
  • Finder’s Fees:
    • Cash Fee: 8.0% of gross proceeds.
    • Broker Warrants: Equal to 8.0% of the number of units issued.
  • Broker Warrant Terms:
    • Exercise Price: Not less than $0.02834 per common share.
    • Duration: 24 months from closing.
    • Condition: Subject to shareholder approval (excluding votes of broker warrant holders); approval to be sought no later than the next annual general meeting. If approval is not received, broker warrants are not exercisable.
  • Hold Period: All securities subject to a statutory hold period of four months and one day from the date of issuance.
Read the original news release →

More from Appili Therapeutics Inc

Jun 26, 2026 · 18:29

Pre-revenue biotech burns through cash, relies on distant government milestones while facing immediate going-concern liquidity crunch.

Earnings Mar 30, 2026 · 07:19

Appili Touts Non-Dilutive Grants as Cash Burn Outpaces Micro-Cap Equity Raises

Other Feb 18, 2026 · 07:19

Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement

Financings Feb 12, 2026 · 18:15

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026

Earnings Dec 18, 2025 · 18:34

Appili closes $177,500 first tranche of placement

Financings Dec 18, 2025 · 07:31

Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

Financings